ArticleScientific reports2018
Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21.
Open access · goldAbstract read
In one paragraph
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 5 pooled it
6.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 5 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- Glioma management and outcome in low-middle-income countries: a systematic review.Frontiers in oncology · 2026Pooled it
- Multi-ancestry genome-wide association study of 4069 children with glioma identifies 9p21.3 risk locus.Neuro-oncology · 2023Pooled it
- Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma.Gastroenterology · 2020Pooled it
- Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility.Nature genetics · 2020Pooled it
- TERT rs10069690 polymorphism and cancers risk: A meta-analysis.Molecular genetics & genomic medicine · 2019Pooled it
- Gene regulatory network analysis identifies dysregulation of hypoxia pathways as contributing to glioblastoma treatment resistance in females.Biology of sex differences · 2026Article
- Gene regulatory network analysis identifies dysregulation of hypoxia pathways as contributing to glioblastoma multiforme treatment resistance in females.medRxiv : the preprint server for health sciences · 2026Article
- Sphingolipid metabolic enzyme GLA expression in gliomas: prognostic implications and therapeutic potential.Frontiers in oncology · 2026Article
- Preoperative inflammatory and molecular marker changes in 125 supratentorial glioma cases.Turkish journal of medical sciences · 2026Article
- Unveiling migraine subtype heterogeneity and risk loci: integrated genome-wide association study and single-cell transcriptomics discovery.The journal of headache and pain · 2025Article
- Sex-Related Differences in Glioblastoma: A Single-Center Retrospective Cohort Study.Biomedicines · 2025Article
- The role of the Ki-67 labelling index as an independent prognostic factor in indonesian glioma patients.Histology and histopathology · 2025Article
- A novel variant of telomerase reverse transcriptase (TERT) associated with risk of glioma in a Korean population.Scientific reports · 2025Article
- Immunotherapy for glioblastoma: current state, challenges, and future perspectives.Cellular & molecular immunology · 2024Review
- Role of the Neanderthal Genome in Genetic Susceptibility to COVID-19: 3p21.31 Locus in the Spotlight.Biochemical genetics · 2024Review
- Region-Based Analyses of Existing Genome-Wide Association Studies Identifies Novel Potential Genetic Susceptibility Regions for Glioma.Cancer research communications · 2024Article
- Differential effects of environmental exposures on clinically relevant endophenotypes between sexes.Scientific reports · 2024Article
- Sex-Specific Differences in Patients withAJNR. American journal of neuroradiology · 2024Article
- Article
- Investigating the shared genetic architecture between frailty and insomnia.Frontiers in aging neuroscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 20 institutions in 6 countries.
Quinn T OstromDepartment of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, United States of America.
Ben KinnersleyDivision of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.ORCID 0000-0003-1783-6296
Margaret R WrenschDepartment of Neurological Surgery and Institute of Human Genetics, School of Medicine, University of California, San Francisco, San Francisco, California, United States of America.
Jeanette E Eckel-PassowDivision of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America.
Georgina ArmstrongDepartment of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, United States of America.
Terri RiceDepartment of Neurological Surgery and Institute of Human Genetics, School of Medicine, University of California, San Francisco, San Francisco, California, United States of America.
Yanwen ChenCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
John K WienckeDepartment of Neurological Surgery and Institute of Human Genetics, School of Medicine, University of California, San Francisco, San Francisco, California, United States of America.
Lucie S McCoyDepartment of Neurological Surgery and Institute of Human Genetics, School of Medicine, University of California, San Francisco, San Francisco, California, United States of America.
Helen M HansenDepartment of Neurological Surgery and Institute of Human Genetics, School of Medicine, University of California, San Francisco, San Francisco, California, United States of America.
Christopher I AmosInstitute for Clinical and Translational Research, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, United States of America.
Jonine L BernsteinDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Elizabeth B ClausSchool of Public Health, Yale University, New Haven, Connecticut, United States of America.
Dora Il'yasovaDepartment of Epidemiology and Biostatistics, School of Public Health, Georgia State University, Atlanta, Georgia, United States of America.ORCID 0000-0003-4290-6794
Christoffer JohansenOncology clinic, Finsen Center, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-4384-206X
Daniel H LachanceDepartment of Neurology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, Minnesota, United States of America.
Rose K LaiDepartment of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.
Ryan T MerrellDepartment of Neurology, NorthShore University HealthSystem, Evanston, Illinois, United States of America.
Sara H OlsonDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Siegal SadetzkiCancer and Radiation Epidemiology Unit, Gertner Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Joellen M SchildkrautDepartment of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, United States of America.
Sanjay SheteDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Joshua B RubinDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Justin D LathiaDepartment of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, United States of America.
Michael E BerensCancer and Cell Biology Division, The Translational Genomics Research Institute, Phoenix, Arizona, United States of America.ORCID 0000-0002-3382-6787
Ulrika AnderssonDepartment of Radiation Sciences, Faculty of Medicine, Umeå University, Umeå, Sweden.
Preetha RajaramanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America.
Martha S LinetDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America.
Zhaoming WangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America.
Meredith YeagerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America.
GliomaScan consortium
Richard S HoulstonDivision of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.
Robert B JenkinsDepartment of Laboratory Medicine and Pathology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, Minnesota, United States of America.
Beatrice MelinDepartment of Radiation Sciences, Faculty of Medicine, Umeå University, Umeå, Sweden.
Melissa L BondyDepartment of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, United States of America.
Jill S Barnholtz-SloanCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America. jsb42@case.edu.ORCID 0000-0001-6190-9304
National Cancer Institute · USUniversity of California, San Francisco · USBaylor College of Medicine · USHarvard University · USMayo Clinic · USUmeå University · SEBrigham and Women's Hospital · USCancer Council Victoria · AUCenters for Disease Control and Prevention · USInstitute of Cancer Research · GBKarolinska Institutet · SEMemorial Sloan Kettering Cancer Center · USUniversity of Southern California · USUniversity of Washington · USUniversity School · USAmerican Cancer Society · USCleveland Clinic · USGeorgia State University · USJohns Hopkins University · USKarolinska University Hospital · SE
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MUCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MTissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4MCALIFORNIA COORDINATED CANCER PREVENTION & CONTROL PROGRAMU58DP003862 · DP · CALIFORNIA STATE DEPT OF PUBLIC HEALTH · PI SNIPES, KURT P · 2012 to 2014
$31.5MGENETIC EPIDEMIOLOGY OF MALIGNANT GLIOMAR01CA052689 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K., WRENSCH, MARGARET R. · 1991 to 2015
$20.5MInternational Case Control Study of Malignant GliomaR01CA139020 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BONDY, MELISSA L. · 2010 to 2015
$16.0MImmune epigenetic biomarkers of survival in glioma epidemiologyR01CA207360 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K. · 2017 to 2021
$3.8MBiomarkers of survival in glioma epidemiologyR01CA126831 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K. · 2008 to 2013
$2.5MNCCDPHP CDC HHS U58 DP003862NCI NIH HHS HHSN261201000034CNCI NIH HHS HHSN261201000035CNCI NIH HHS HHSN261201000035INCI NIH HHS HHSN261201000140CNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA097257NCI NIH HHS R01 CA052689NCI NIH HHS R01 CA126831NCI NIH HHS R01 CA139020NCI NIH HHS R01 CA207360NCRR NIH HHS UL1 RR024131Wellcome Trust
Abstract
Incidence of glioma is approximately 50% higher in males. Previous analyses have examined exposures related to sex hormones in women as potential protective factors for these tumors, with inconsistent results. Previous glioma genome-wide association studies (GWAS) have not stratified by sex. Potential sex-specific genetic effects were assessed in autosomal SNPs and sex chromosome variants for all glioma, GBM and non-GBM patients using data from four previous glioma GWAS. Datasets were analyzed using sex-stratified logistic regression models and combined using meta-analysis. There were 4,831 male cases, 5,216 male controls, 3,206 female cases and 5,470 female controls. A significant association was detected at rs11979158 (7p11.2) in males only. Association at rs55705857 (8q24.21) was stronger in females than in males. A large region on 3p21.31 was identified with significant association in females only. The identified differences in effect of risk variants do not fully explain the observed incidence difference in glioma by sex.
Indexed as
AdultAllelesBrain NeoplasmsCase-Control StudiesChromosomes, Human, Pair 3Chromosomes, Human, Pair 7Chromosomes, Human, Pair 8FemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeGliomaHumansLogistic ModelsMaleMiddle Aged
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.